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Edited by Veli-Pekka LehtoAbstract The structural characteristics of the three nuclear
phosphoproteins of the high mobility group A family are outlined
and related to their participation in chromatin structure alter-
ation in many biological processes such as gene expression,
neoplastic transformation, diﬀerentiation, and apoptosis. The
elevated expression of these proteins in tumor cells and their
post-translational modiﬁcations, such as phosphorylation, acet-
ylation and methylation, are discussed and suggested as suitable
targets for cancer chemotherapy.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Epigenetic process; Cancer1. Introduction: HMGA, nuclear proteins highly expressed
following neoplastic transformation
Since the early identiﬁcation of high mobility group A
(HMGA) proteins in rat thyroid cells transformed by retro-
viruses, we realized that they were strongly related to cancer
because their level of expression was much higher in the
transformed cells compared to normal cells in which they re-
sulted practically absent [1,2]. We described a group of three
proteins (named C, D, and E) identiﬁed in neoplastic cells by
electrophoretic analyses. These proteins showed a high elec-
trophoretic mobility both in SDS and acetic acid/urea PAGE,
similar to that reported by Johns and Goodwin for a group of* Corresponding author. Fax: +39-040-5583694.
E-mail address: giancot@bbcm.units.it (V. Giancotti).
Abbreviations: ERCC1, excision repair cross-complementing group 1;
HIV-1, immunodeﬁciency virus type 1; HMGA, high mobility group A
proteins; HPLC, high performance liquid chromatography; HPV 18,
human papilloma virus 18; IFN-b, interferon-b; IL-2Ra, interleukin-2
receptor-a; IR, insulin receptor; LC-MS, liquid chromatography-mass
spectrometry; MARs/SARs, matrix/scaﬀold associated regions; PTMs,
post-translational modiﬁcations; SRF, serum response factor; TF,
transcription factor
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doi:10.1016/j.febslet.2004.08.013nuclear proteins characteristic of all mammalian cells and
named HMG [3]. This group comprised the HMG1, HMG2,
HMG14, and HMG17 proteins. At the same time, Goodwin
and co-workers [4] identiﬁed two new proteins in the nuclei of
rat thymus and of ﬁbroblasts transformed with avian sarcoma
virus. These proteins were named I and I0 because of their
resemblance to two proteins named Y and I, previously found
by Lund et al. [5] in HeLa cells. In the same period, A. Var-
shavsky’s group [6] studied the binding to the DNA of a
mammalian protein called a subsequently found to be an
HMG protein. When sequence information became available
[7,8], this allowed the restriction of the new HMG proteins to a
set of only three polypeptides that were almost universally
reported as HMGI (previously I, D, a), HMGY (previously Y,
E), and HMGI-C (previously I0, C). Recently [9], researchers in
this ﬁeld decided to rationalize the nomenclature of all HMG
proteins as previously done for histone nomenclature. There-
fore, the three proteins, subject of this mini-review, are
grouped together in the HMGA family that comprises
HMGA1a, HMGA1b, and HMGA2 (previously HMGI,
HMGY, and HMGI-C, respectively).2. HMGA structure and interaction properties
HMGA1a, HMGA1b and HMGA2 are polypeptides of
about one hundred amino acid residues characterized by a
modular sequence organization as shown in Fig. 1. Two dif-
ferent genes are responsible for their expression: HMGA1 and
HMGA2: the ﬁrst gene produces both HMGA1a and
HMGA1b by alternative splicing, the second gene HMGA2
[7,8]. These proteins have three highly positively charged re-
gions (highlighted in yellow in Fig. 1A) called AT-hooks, since
they bind the minor groove of AT-rich DNA stretches. On the
contrary, the C-terminus has completely diﬀerent feature since
it contains a high percentage of negatively charged acidic
residues (highlighted in red in Fig. 1A). As shown in Fig. 1B,
the three AT-hooks are diﬀerently spaced along the protein
molecules resulting in an interactive modular system consti-
tuted by a set of three proteins able to establish interactions
with diﬀerently spaced AT-rich DNA regions. The HMGA
proteins show an unusual capability to bind other nuclearblished by Elsevier B.V. All rights reserved.
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Fig. 1. Primary structure and some proposed functions of human HMGA proteins in the nucleus. (A) Amino acid residues sequences of HMGA1a,
HMGA1b, and HMGA2 proteins. AT-hooks (AT) are evidenced in yellow, the C-terminus in red. Note the only diﬀerence between HMGA1a and
HMGA1b due to the stretch of 11 amino acid residues following the ﬁrst AT-hook. (B) Scheme of the sequences of HMGA proteins pointing out to
the diﬀerently spaced AT-hooks (in yellow) and C-terminal ends (in red) along the three protein molecules. (C) Scheme illustrating some of the most
important activities of HMGA proteins. c1: An HMGA protein directly binds to the DNA (1) modifying its conformation and consequently fa-
cilitating the binding of a group of other TFs (2). HMGA proteins interact with both DNA and TFs generating a multiproteic stereospeciﬁc complex
bound to DNA [18]. c2: An HMGA protein interacts with a TF (1) that has low aﬃnity for DNA, modifying its conformation (2) and allowing its
binding to DNA with high aﬃnity [15,19]. c3: De-repression of transcription by displacement of histone H1 by HMGA proteins [20].
2 R. Sgarra et al. / FEBS Letters 574 (2004) 1–8proteins, as reﬂected by the growing number of HMGA mo-
lecular partners [10]. Neither secondary nor tertiary structure
has been determined for HMGA proteins free-in-solution, but
this does not exclude that in vitro and in vivo interactions
could result in locally speciﬁc non-canonical structures fol-
lowing the binding with DNA and/or other proteins. Indeed,
the core element of AT-hooks is indicated as a motif that as-
sumes a deﬁned structure able to induce structural changes on
DNA such as bending, straightening or unwinding [10,11].
Moreover, although diﬀerent regions have been identiﬁed inHMGA proteins as sites of interaction with other nuclear
factors, the one most frequently involved in protein–protein
interaction comprises the second AT-hook and the amino acid
residues between the second and the third AT-hook [12–17].3. Multiple functions of HMGA proteins
HMGA proteins, short and ﬂexible molecules containing
diﬀerent interacting domains, are able to wedge into many
R. Sgarra et al. / FEBS Letters 574 (2004) 1–8 3diﬀerent compartments assembling or modulating macromo-
lecular complexes that are involved in a variety of biological
processes. Indeed, many reports illustrate how HMGA pro-
teins participate in processes such as the regulation of gene
expression, virus integration and expression, embryogenesis
and diﬀerentiation, and neoplastic transformation. Fig. 1C
shows a diagram in which some of the proposed functions of
HMGA in the nucleus are highlighted.
3.1. HMGA proteins in the regulation of gene expression
HMGA proteins have been shown to participate in the
regulation of many genes, but one of the best-studied mecha-
nisms of gene regulation in which they are involved is that of
the interferon-b (IFN-b) gene. The activation of the IFN-b
expression is due to a multifactor complex that assembles in
the nucleosome-free enhancer region of the gene, formed by
the factors NF-jB, IRF, ATF2/cJun, and the HMGA1a pro-
tein [18,21]. HMGA1a plays a double function in this context:
(i) induces allosteric changes in the DNA thus increasing the
aﬃnity of the transcription factors (TFs) for their binding sites
and (ii) establishes protein–protein interactions with the same
factors. This new structure, called enhanceosome, is responsi-
ble for the modiﬁcation and the remodeling of a nucleosome
that masks the TATA-box; consequently, transcription can
start. This remodeling is triggered by the recruitment from the
enhanceosome of GCN5/PCAF that acetylates the nucleosome
and also HMGA1a at K64, the latter modiﬁcation resulting in
the stabilization of the enhanceosome. Later, another acetyl
transferase called CBP modiﬁes HMGA1a at K70 destabiliz-
ing the enhanceosome and, consequently, repressing
transcription.
The recruitment on the promoter/enhancer element of
chromatin of remodeling factors by gene-speciﬁc macromo-
lecular complexes is thought to be a widespread mechanism
for gene activation. It is therefore important to underline
that the HMGA participate, acting in a manner very similar
to that reported for the IFN-b gene, in the regulation of a
large set of genes two examples of which are the interleukin-2
receptor-a (IL-2Ra) and the insulin receptor (IR) genes
[22,23].
HMGA can inﬂuence gene transcription also through direct
protein–protein interactions with TFs by inducing changes in
their DNA binding aﬃnities. The enhancement of the serum-
response factor (SRF) transcriptional activity by HMGA1a is
an example of this mechanism [15].
Moreover, given their high abundance in cancer cells, the
HMGA have the ability to alter chromatin structure. Indeed,
they have been shown to be important elements associated
with MARs. MARs/SARs (matrix/scaﬀold associated regions)
are speciﬁc segments of genomic DNA that have high aﬃnity
for the nuclear matrix and that are enriched in AT sequences.
These sequences anchor chromatin to the nuclear scaﬀold and
organize topologically independent DNA domains which have
functional roles both in DNA replication and transcription
[24]. It has been demonstrated that HMGA proteins displace
Histone H1 from MARs, thus participating in chromatin
transcriptional activation [20].
3.2. HMGA proteins in virus integration and expression
Further striking importance of the role of HMGA proteins
has been evidenced in both virus integration and viral genome
expression in host cells [25–28]. Indeed, it has been demon-strated that the pre-integration complex by which immuno-
deﬁciency virus type 1 (HIV-1) becomes a part of the host
genome of the infected cells contains as an essential compo-
nent the HMGA1a protein, which is supplied by the host cell.
Moreover, the same protein cooperates with the hSWI/SNF
complex at the HIV-1 promoter in order to modify chromatin
structure and activate the transcription of the viral genes.
Similar studies have been also carried out for human papil-
loma virus type 18 (HPV 18) in which it has been demon-
strated that the core of the enhanceosome that stimulates
transcription is formed by the hetero-dimers JunB/Fra2 and
HMGA1a.
3.3. HMGA proteins in embryogenesis and diﬀerentiation
In normal cells the expression of HMGA proteins is re-
stricted to embryogenesis, it decreases with organogenesis and
in normal adult cells is very low or almost absent. In partic-
ular, both genes are expressed at high levels in the entire em-
bryo until 8.5 dpc [29,30]. At later stages, the expression
pattern becomes more restricted; in particular, HMGA1 ex-
pression is conﬁned to speciﬁc body organs of ectodermal,
mesodermal and endodermal origin, while HMGA2 expression
is restricted to mesenchimal tissues. A role for both factors in
development has been demonstrated. Pivotal studies carried
out by Chada’s group demonstrated that mice showing a
pygmy phenotype carry a disrupted Hmga2 gene and are
characterized by a large reduction of fat tissue [30]. The same
group conﬁrmed the role of HMGA2 in adipogenesis, dem-
onstrating that the deﬁciency of the Hmga2 gene in mice re-
sults in resistance to obesity induced by diet [31]. The
phenotype of Hmga1 knockout mice has not been reported
possibly because the more general expression of this factor
could severely impair development. Indeed, suppression of
HMGA1 expression impairs diﬀerentiation of pre-adipocytic
cells [32], loss of Hmga1 gene function aﬀects lymphohemat-
opoietic diﬀerentiation [33] and Hmga1 is required for normal
sperm development [34].
3.4. HMGA proteins in neoplastic transformation
After embryogenesis, HMGA are re-expressed at high levels
in transformed cells and in tumors. This elevated expression,
detected in a variety of tumors having diﬀerent origins [35–38],
prompted us and other laboratories to suggest HMGA1a and
HMGA1b as diagnostic markers of neoplastic transformation/
progression. Indeed, it has been well established by immuno-
histochemistry [39–48] that many human neoplasias, including
thyroid, prostatic, cervical, colorectal, pancreatic and ovarian
carcinoma, show a strong increase of HMGA1a and
HMGA1b proteins [40–46,48]. The ﬁrst evidence of a direct
role played by these factors in tumorigenesis came from
transfection in normal rat thyroid cells of an antisense con-
struct for HMGA2 that prevented retrovirally induced neo-
plastic transformation [49]. The increased expression of
HMGA proteins was later shown to promote tumor progres-
sion in diﬀerent cell lines. Overexpression of the three HMGA
proteins led to transformation with anchorage-independent
growth in Rat 1a ﬁbroblasts and human lymphoid CB33 cells
and similar results have been obtained by overexpressing the
HMGA1a in the human breast epithelial cell line MCF-7 [50–
53]. Transgenic mice overexpressing HMGA proteins con-
ﬁrmed the role of these proteins in tumorigenesis also in vivo
[54,55].
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result of speciﬁc chromosomal rearrangements has also been
reported in a variety of common benign tumors. Structural
alterations for both HMGA genes have been reported, but
rearrangements of the HMGA2 gene at 12q15 are particularly
frequent especially in lipomas and leiomyomas, making this
gene probably the most commonly rearranged one in human
neoplasms. The pivotal role of HMGA2 rearrangements in the
process of lipomagenesis has been previously reviewed [56].4. Modiﬁed forms of HMGA proteins
HMGA proteins are subjected to a variety of post-transla-
tional modiﬁcations (PTMs) that modulate their multi-inter-
acting property with both DNA and proteins [57–67].
Radioactive labeling and liquid chromatography/mass spec-
trometry (LC/MS) are techniques of choice for the identiﬁca-
tion of protein post-translational modiﬁed forms. We used LC/
MS to study changes of HMGA PTMs in diﬀerent cell lines
subjected to diﬀerent stimuli. Protein samples containing all
families of HMG proteins have been obtained by extraction of
tumor cells with perchloric acid [2,35] and then analyzed by
reverse-phase chromatography in order to separate HMGA
proteins from the other two HMG families, i.e., HMGB
(formerly HMG1/2) and HMGN (formerly HMG14/17)Fig. 2. LC-MS analysis of a protein sample obtained by 5% perchloric acid
HPLC proﬁle obtained by a water/acetonitrile gradient using a C18 column
group; M, methyl group (peaks highlighted in yellow). (C) Comparison of exp
values calculated according to the amino acid residue sequence.[3,9,68], still present in neoplastic cells. A typical chromato-
graphic proﬁle of the ﬁve low molecular mass HMG proteins
(HMGA1a, HMGA1b, HMGA2, HMGN1, and HMGN2) is
shown in Fig. 2A. Mass spectrometric analysis allows the
identiﬁcation of all the modiﬁed forms as shown in Fig. 2B, in
which it is possible to note that more than one species co-elute
in the same chromatographic peak. As shown in Fig. 2C, ex-
perimental masses can be compared with theoretical ones de-
duced from the amino acid sequences of Fig. 1A. HMGA
proteins are among the most highly post-translationally
modiﬁed nuclear proteins. Fig. 3 summarizes PTM sites of the
HMGA1a protein so far identiﬁed by our and other labora-
tories [18,58–67].
4.1. Phosphorylation
Nearly all of HMGA1a and HMGA1b proteins are consti-
tutively phosphorylated by casein kinase 2 (CK2) at the two or
three serine residues of the C-terminal end (see Fig. 1A),
however, the function of this constitutive phosphorylation is
not clearly understood [58–67]. Experimental evidence ob-
tained on the HMGA2 protein suggests that the acidic tail
could have a role in the transcriptional regulation of target
genes by regulating the DNA-binding aﬃnity rather than
speciﬁcity [69,70]. Phosphorylation of the serines located at the
C-terminus could therefore represent an additional modula-
tion of HMGA DNA-binding properties. Moreover, otherextraction from the prostate tumor cell line PC-3. (A) Reverse-phase
. (B) Reconstructed mass spectra obtained by LC-MS. P, phosphate
erimental mass values of detected HMG proteins and theoretical mass
K 64(A)
K 70(A)
T52(P) T77(P)
S98(P)
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S102(P)
T20(P)
S43(P)
PKC
CK2
P/CAF
CBP
AT AT AT COOHCH3CONH
R 25(M)
1 106
S63(P)
Fig. 3. Schematic description of post-translational modiﬁcations found
for human HMGA1a protein. AT, AT-hook; P, phosphorylation site;
A, acetylation site; M, Methylation site; PKC, protein kinase C; P/
CAF and CBP, acetyl transferases; CK2, casein kinase 2; cdc2, cdc2
kinase. Apex numbers at the amino acid symbols indicate the position
of the modiﬁed residue along the protein sequence.
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cell cycle, such as those at T52 and T77 due to cdc2 kinase, or
to signal transduction pathways such as T20, S43, and S63 that
are modiﬁed by protein kinase C (PKC). Phosphorylation of
T52 and T77 of the human HMGA1a protein takes place at
G2/M-phase of the cell cycle and causes a strong decrease of
the DNA-binding aﬃnity [62,71]. On the other hand, phos-
phorylation by PKC of T20, S43, and S63 is the result of the
treatment of mammary epithelial cells with phorbol esters that
activate the Ca2þ/phospholipid pathway [61]. Likewise the
cdc2 phosphorylation, a signiﬁcant reduction of DNA-binding
aﬃnity has been found for HMGA1a protein modiﬁed by
PKC. Detailed studies carried out by J.R. Wisniewski and
coworkers elegantly diﬀerentiated the aptitude of the three AT-
hooks and of the three proteins (see Fig. 1A and B) to bind to
the DNA [72,73]. Using the promoter region of the IFN-b gene
as a model, these authors demonstrated that the two proteins
HMGA1a and HMGA1b engage all three AT-hooks in
binding DNA, whilst the HMGA2 protein employs its N-ter-
minal and central AT-hooks. Phosphorylation of HMGA1b
by cdc2 kinase impairs the contacts of the ﬁrst AT-hook with
the IFN-b promoter, whereas phosphorylation of HMGA2
by the same kinase aﬀects mainly the binding of the second
AT-hook.4.2. Acetylation
HMGA are costitutively N-terminally acetylated (Fig. 3);
the function of K64 and K70 acetylation in the context of
IFN-b enhanceosome structure has been already discussed.4.3. Methylation
Methylation is the most recent HMGA modiﬁcation that
has been taken into consideration [59–61,67]. By mass
spectrometry analysis of trypsin-digested HMGA1a, we
demonstrated that this protein, at least in the analyzed cells,
is mono-methylated at R25 that is located in the middle of
the ﬁrst AT-hook (see Fig. 1A). With regard to this
modiﬁcation, two points are worthwhile to mention: (i) in
the analyzed tumor cells, the percentage of mono-methylated
HMGA1a protein is very high reaching in some samples up
to ﬁfty per cent of total HMGA1a protein and (ii)among HMGA proteins only HMGA1a resulted methyl-
ated, at least at the level of sensitivity of the adopted
method.
4.4. PTMs conclusive remarks
Results similar to those reported in Fig. 2 have been ob-
tained for many other neoplastic cells and taken together allow
us to draw the following conclusions:
• HMGA1a and HMGA1b are usually detectable in tumor
cells and, in addition to these proteins, many highly trans-
formed cells express also the HMGA2 protein;
• HMGA proteins are constitutively bi- or tri-phosphory-
lated at their C-terminus;
• The three HMGA proteins are not equivalently modiﬁed by
PTMs;
• Many neoplastic cell lines show large amounts of mono-
methylated HMGA1a protein that appears to be the only
HMGA protein methylated at high level.5. HMGA proteins and apoptosis
The most extended variation in HMGA PTMs seems to
occur during programmed cell death chromatin condensa-
tion. We carried out detailed LC/MS studies on the
HMGA1a protein of a number of tumor cells induced to
undergo apoptosis by various procedures [59,60,67]. At early
apoptotic stages, the HMGA1a protein undergoes an in-
crease in the degree of phosphorylation that probably results
in its displacements from DNA and, consequently, allows
faster DNA digestion because of the more accessible chro-
matin structure. These new phosphate groups added to those
already present at the C-terminal tail result in hyper-phos-
phorylated forms (up to 5 phosphates/protein molecule).
Hyper-phosphorylation is followed by a de-phosphorylation
process that, depriving HMGA1a protein of many negative
charges, facilitates re-aggregation of DNA and the place-
ment of HMGA into apoptotic bodies. On the contrary,
during apoptosis, there is a continuous increase of the de-
gree of HMGA1a methylation at R25 that reaches the
highest level when completely de-phosphorylated protein is
observed. The function of this modiﬁcation is currently
under investigation.6. Conclusion and perspectives
Core histones (H2A, H2B, H3, and H4) organize the DNA
into ﬁbers that are further compacted by linker histone H1
[74]. The compactness of this structure is variously modulated,
depending on the necessities of the cell, by loss or weakness of
binding of histone H1, by post-translational modiﬁcation of
N-sides of core histones, and by the interference of other non-
histone nuclear proteins. Among these, HMGA proteins play
an important role since:
(a) They are present in large amounts in the nucleus (particu-
larly in tumor cells).
(b) They compete with histone H1 to bind to the DNA.
(c) They are capable of forming multiprotein complexes in-
volved in DNA-binding.
(d) They are, to a great degree, subjected to several PTMs.
6 R. Sgarra et al. / FEBS Letters 574 (2004) 1–8HMGA proteins participate locally and temporally to the
dynamic modiﬁcation of the chromatin structure, mainly im-
posed by the histones, and, therefore, they have been deﬁned
‘‘architectural factors’’ [68,74,75]. Consequently, cells that ex-
press high levels of HMGA proteins (such as tumor cells)
should have a profound alteration in the chromatin structure
when compared with normal cells.
In addition to being a particular ‘‘feature’’ of transformed
cells, a number of papers have pointed out to the oncogenic
activity of HMGA at least in some selected cell lines [49–56].
For all these reasons, the HMGA proteins could represent a
good target for the development of new anticancer strategies.
Actually, in order to interfere with their function or block their
expression, some papers reported the use of antisense tech-
nology in cancer cells to suppress the expression of HMGA
proteins that leads to a decrease in cell proliferation or to
apoptotic cell death [48,76,77]. Moreover, an already known
antitumoral drug named FR900482 [78] has been suggested as
cross-linking agent of HMGA1a and HMGA1b to the minor
groove of DNA in order to avoid any further use of the protein
in the nucleus [79].
Another, not yet explored, way to prevent the action of
HMGA proteins could be found in their natively disordered
structure that is able to establish multiple interactions. It is
conceivable that HMGA proteins could be forced to assume
a ﬁxed structure, thereby loosing the original multi-inter-
acting capability. This modiﬁcation could be obtained by
introducing or producing into tumor cells speciﬁc com-
pounds able to turn a ﬂexible molecule into a rigid and no
further on usable one. A deeper understanding of the
HMGA molecular network of protein–protein interaction
could provide essential information for the development of
such a chemotherapeutic agent. Following this idea, in our
laboratory we have already started a proteomic project to
search for HMGA molecular partners. The preliminary
HMGA molecular network we obtained suggests an in-
volvement of HMGA proteins not only at a transcriptional
level but also in other basal nuclear DNA- and RNA-linked
processes [manuscript in preparation]. Identifying HMGA
molecular partners and subsequently the domains/structures
involved in HMGA protein–protein contacts could provide
unchallenged opportunities to develop molecules able to
selectively perturb the various activities of HMGA proteins.
However, it is our opinion that HMGA proteins should be
targeted in combination therapies in which there are at least
two targets: the ﬁrst speciﬁc and characteristic of a stated
tumor (such as an inhibitor of a speciﬁc kinase or siRNA
against speciﬁc mRNAs), the second with a general inﬂuence
on chromatin (such as histones or HMGA proteins).
In many tumor cells, the HMGA2 protein is overexpressed
in addition to the other two proteins. Until now, the reason for
this extra-expression is not known but our recent results sug-
gest that HMGA2 is involved in cell-cycle control by regu-
lating the cyclin A gene [17]. Indeed, HMGA2 knockout mice
show the pygmy phenotype, which is characterized by growth
retardation and a drastic reduction of body fat content [30].
Moreover, it was also shown that HMGA2 can negatively
aﬀect the expression of DNA-repair gene ERCC1, linking
therefore HMGA2 expression with genomic instability [80].
These results suggest that HMGA2 could be related to pro-
liferation rather than neoplastic transformation. However,
repression of this protein could be an attractive tool for acombined chemotherapeutic treatment, at least for a limited
group of cancers.
The epigenetic modiﬁcation of chromatin takes into ac-
count also the methylation process that should be discussed
from a triplicate point of view. (i) DNA methylation at the
5-position of cytosine in the di-nucleotide sequence CpG is a
well-known phenomenon and hyper-methylation of DNA
promoter regions has been associated with transcriptional
silencing of tumor suppressor genes [81,82]. (ii) Histone
methylation also seems to be associated with repressive
chromatin structure formation that brings DNA into inac-
tive heterochromatin [83]. (iii) The third methylation is that
of HMGA1a that reaches high levels in tumor cells [59,60].
It could be possible that also methylated HMGA1a is in-
volved in the silencing program in which both DNA and
histone methylation participate. Inhibition of methyltransfe-
rases that catalyze the three types of methylation could be a
very promising tool in cancer therapy. Studies on both DNA
and histone methylation are more advanced compared to
those concerning the HMGA proteins. Indeed, clinical trials
are already carried out with decitabine (NSC-127716, Da-
cogen, Supergen) that is a speciﬁc DNA methyltransferase
inhibitor used in order to reduce the chromatin repression
pathway.
In conclusion, the scenario of epigenetic modiﬁcations of
DNA and chromatin associated proteins is wide and includes
many diﬀerent events that, however, are linked and cooperate
in cancer cell chromatin remodeling. Among these factors and
modiﬁcations there are HMGA proteins, whose function in
chromatin structure alteration is at the moment of increasing
interest in many laboratories.
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